Collaborating with researchers and thought leaders

In collaboration with researchers and thought leaders around the world, OneCell uses scientific expertise and cutting-edge innovation to help drive cancer care to new frontiers. Below are some of our key publications.

True single-circulating tumor cell genomics reveals enriched therapy-resistance signatures in advanced colorectal cancer patients.(Read Abstract)

Poster Presentation

  1. Longitudinal ctDNA monitoring with resistance genomic signatures show poor prognostication in EGFR-mutated advanced NSCLC patients. (Read Abstract)

  2. Single live circulating tumor cells capture and their genomic profile reveal enriched mutations of PIK3CA and HRR pathway in breast cancer patients. (Read Abstract)

  3. Genomic profile of true single circulating tumor cells (sCTC) from hepatocellular carcinoma reveals novel mutational features.(Read Abstract)

  4. Effect of circulating tumor cells in clinically stable patients demonstrates the conundrum of recurrence with cellular residual disease. (Read Abstract)

  5. Complementing circulating tumor DNA and circulating tumor cells load discriminate stable and progressive disease in treated patients. (Read Abstract)

  6. Circulating tumor DNA genomic mutations and circulating tumor cells biomarker duo show clinical concordance in localized,progressive, and metastatic disease. (Read Abstract)

  7. Immune-cold solid tumors exhibit therapeutic potential through homologous recombination deficiency. (Read Abstract)

  8. Measure of minimal residual burden on circulating tumor cells with over-expression of programmed death-ligand 1 as adynamic biomarker in colorectal cancer patients. (Read Abstract)

  9. Circulating tumor cells (CTC) and CTC clusters with PD-L1 dynamic biomarker show minimal cellular burden in ovarian cancer patients. (Read Abstract)

  10. Comparative genomic profiling of circulating tumor DNA and paired Formalin-Fixed Paraffin- Embedded (FFPE) DNA from Indian breast cancer patients. (Read Abstract)

Poster Presentation

  1. Distribution prophecy of circulating tumor cell clusters in CTC populace patients of epithelial cancers (Read Abstract)

  2. Evaluation ofHER-2 expression on circulating tumor cells as a real time biomarker in advanced breast cancer (Read Abstract)

  3. Comprehensive genomic profiling of ctDNA reveals distinct genomic signatures and therapeutic implications for immunotherapy response in advanced head and neck cancer (Read Abstract)

  4. Comprehensive mutational profile of true single circulating tumor cells compared with CtDNA in advanced pancreatic adenocarcinoma (Read Abstract)

  5. Capturing live single circulating tumor cells platform for comprehensive genomic profiling with paired ctDNA in breast cancer patients (Read Abstract)

True single circulating tumor cells (sCTC) genomic signatures exhibit early drug resistance   signatures in metastatic cancer patients.

Abstracts

  1. Comprehensive plasma genotyping of patients with EGFR positive NSCLC as a monitoring tool for therapy response and disease progression. Read abstract.

  2. Effect of circulating tumor cells distribution in treatment naive and treated patients with advance stage breast cancer on disease burden. Read abstract.

  3. Mutational profiling of true single circulating tumor cells (sCTC) in metastatic lung cancer to determine genomic heterogeneity and drug-resistance signatures. Read abstract.

  4. Identification of SNVs via targeted comprehensive genome profiling in patients with brain cancer. Read abstract.

  5. Identification of novel actionable SNVs via targeted comprehensive genome profiling in patients with gallbladder and cholangiocarcinoma cancer. Read abstract.

  6. Identification of novel actionable SNVs using targeted comprehensive genome profiling in patients with sarcoma. Read abstract.

  7. Circulating tumor cells (CTCs) detection and isolation in different subtypes of early-stage breast cancer patients from Bangladesh. Read abstract.

  8. Comprehensive ctDNA analysis to identify genome-instability and actionable mutation landscape in gynecologic cancers. Read abstract.

  9. Comprehensive plasma genotyping reveals mutational signatures that confer resistance to tyrosine kinase inhibitors (TKI) in patients with advanced lung cancer. Read abstract.

Poster Presentations

  1. Detection of PD-L1, HER2 and EGFR on circulating tumor cells in carcinoma patients. Cancer Res 83, 2023. Read abstract.

  2. Comprehensive circulating tumor DNA and CTC profiling of treatment naïve early-stage head and neck cancer patients reveals early signature of disease progression. Cancer Res 83, 2023. Read abstract.

  3. AI-enabled Prediction of lung cancer specific hot spot gene alterations from histology images. Cancer Res 83, 2023. Read abstract.

  4. Comprehensive ctDNA profiling reveals potential Metastatic Genomic signatures in treatment- naive early-stage Breast Cancer Patients. Cancer Res, 83, 2022. Read abstract.

Abstracts

  1. Circulating tumor cells as a biomarker for monitoring - disease progression, treatment response, and minimal residual disease. J Clin Oncol 40, 2022. Read abstract.

  2. A feasibility study of EMF(Erlotinib+Methotrexate+5-Fluorouracil) regimen in recurrent head and neck squamous cell carcinoma (HNSCC) and role of circulating tumour cells (CTCs) in assessment of outcomes. J Clin Oncol 40, 2022. Read abstract.

  3. Correlation of circulating tumor cells as a positive interventional biomarker in cancer patients. J Clin Oncol 40, 2022. Read abstract.

  4. Extracorporeal microchannel device to capture and eliminate circulating tumor cells from cancer patient’s blood. J Clin Oncol 40, 2022. Read abstract.

  5. Machine learning (ML) enabled circulating tumor cells-based classification of patients for non- prerequisite adjuvant therapy. J Clin Oncol 40, 2022. Read abstract.

  6. AI-enabled identification prediction of homologous recombination deficiency (HRD) from histopathology images. J Clin Oncol 40, 2022. Read abstract.

Comprehensive ctDNA profiling reveals potential Metastatic Genomic signatures in treatment-naive early-stage Breast Cancer Patients. Cancer Res, 83, 2022. Read abstract.

Circulating tumor cells demonstrate a positive biomarker in head and neck squamous cell carcinoma (HNSCC) in tobacco consuming population of Bangladesh. J Clin Oncol 39, 2021 Read abstract.

ESMO – MAP 2021

Validation of Cytokeratin (CK18) Protein Expression in Epithelial Cell lines and in Circulating Tumor Cells (CTCs). Annals of Oncology 32, 2021. Read abstract.

1. Correlation of CTCs with disease progression in Indian oral cancer patients. J Clin Oncol 38, 2020. Read abstract.

2. Device for the enumeration and continuous removal of circulating tumor cells in improving overall survival of epithelial cancer patients. J Clin Oncol 38, 2020.Read abstract.

Clinical correlation of circulating tumor cells as a blood marker in Indian head and neck cancer patients. Clin Cancer Res 26, 2020. Read abstract.

A highly efficient, low-cost, novel multicomponent nanosystem for rapid enumeration of circulating tumor cells. J Clin Oncol 37, 2019. Read abstract.

Smriti Arora, Alain D'Souza, Gourishankar Aland, Narendra Kale, Bhagwat Jadhav, Trupti Kad, Pankaj Chaturvedi, Balram Singh, Jayant Khandare. Antibody mediated cotton-archetypal substrate for enumeration of circulating tumor cells and chemotherapy outcome in 3D tumors. Lab on a Chip; 2022; 22 (8); 1519-1530. 

https://pubs.rsc.org/en/content/articlelanding/2022/LC/D2LC00004K

Burhanuddin Qayyumi, Atul Bharde, Gourishankar Aland, Alain D'Souza, Sreeja Jayant, Nitin Singh, Swati Tripathi, Reecha Badave, Narendra Kale, Balram Singh, Smriti Arora, Isha Gore, Arjun Singh, Aravindan Vasudevan, Kumar Prabhash, Jayant Khandare, Pankaj Chaturvedi. Circulating tumor cells as a predictor for poor prognostic factors and overall survival in treatment naïve oral squamous cell carcinoma patients. Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology; 2022; 134 (1); 73-83.

https://www.oooojournal.net/article/S2212-4403(22)00854-9/fulltext

Gowhar Shafi, Shivamurthy P M, Anand Ulle, Krithika Srinivasan, Aravindan Vasudevan, Vikas Jadhav, Dr Sujit Joshi, Nirmal Vivek Raut, Jayant Khandare, Mohan Uttarwar, Kenneth Joel Bloom. AI-enabled identification prediction of homologous recombination deficiency (HRD) from histopathology images. Journal of Clinical Oncology; 2022; 40; 3019-3019.

https://ascopubs.org/doi/abs/10.1200/JCO.2022.40.16_suppl.3019

Manoj Dongare, Gowhar Shafi, Atul Bharde, Fauzul Moubeen, Kanchan Hariramani, Alain D’Souza, Bhagwat Jadhav, Trupti Kad, Sangeeta Prajapati, Manoj Kumar Kumaran, Sumit  Haldar, Vatsal Mehra, Vikas Jadhav, Sujit Joshi, Sreeja Jayant, Gourishankar Aland, Richa Dave, Aravindan Vasudevan, Mohan Uttarwar, Jayant Khandare. Comprehensive ctDNA profiling reveals potential Metastatic Genomic signatures in treatment-naive early-stage Breast Cancer Patients. Cancer Res; 2023; 83

https://ascopubs.org/doi/abs/10.1200/JCO.2022.40.16_suppl.1547